Cancer Immunotherapy Innovators Break New Ground in Antibody Engineering

Sponsored:

Wednesday, October 29, 2025

As the biotech sector continues to evolve, breakthroughs in antibody technology are reshaping the landscape of cancer treatment. With the global oncology market projected to exceed $500 billion by 2030, developers at the cutting edge of immune modulation are racing to design therapies that not only attack tumors but also enhance the body’s own defense systems. Among the most promising approaches are tri-specific antibodies—complex, next-generation biologics designed to engage multiple immune pathways simultaneously.

Shares of Purple Biotech Ltd. (NASDAQ: PPBT) surged 81.8% to $1.06 on Wednesday after the company announced a major manufacturing milestone for IM1240, the first tri-specific antibody from its CAPTN-3 platform. The achievement marks the successful production of a commercially viable yield, positioning the program competitively as it advances toward clinical development and an Investigational New Drug (IND) submission planned for 2026.

According to CEO Gil Efron, this milestone represents a “major step” for the company’s development pipeline. “We have developed a high-efficiency manufacturing and purification process that is designed to deliver a differentiated T cell engager with a capped, cleavable polypeptide designed to help prevent off-tumor immune activation,” said Efron. The breakthrough, he added, demonstrates the scalability and competitiveness of Purple Biotech’s tri-specific antibody platform.

Dr. Michael Schickler, Head of Clinical and Regulatory Affairs, highlighted the scientific complexity of the achievement. “Producing a tri-specific protein such as IM1240 at high yield and purity was perceived as a significant challenge—one that I’m pleased to have successfully mastered,” he said. IM1240 is designed with a triple mechanism of action, engaging both T cells and NK cells to mount a potent, localized anti-tumor immune response. Its innovative structure includes a protease-cleavable cap that prevents unwanted systemic immune activation, potentially improving safety and extending half-life.

The CAPTN-3 platform represents a new frontier in targeted cancer therapy. By conditionally activating tri-specific antibodies within the tumor microenvironment, the platform confines therapeutic activity to cancerous tissue while sparing healthy cells. IM1240 specifically targets 5T4, a tumor-associated antigen linked to advanced disease and poor clinical outcomes in a variety of solid tumors.

Purple Biotech’s broader pipeline includes IM1305, another tri-specific antibody targeting TROP2, and two additional programs—CM24 and NT219—focused on novel immune evasion and resistance pathways. With today’s milestone, the company underscores its growing leadership in the design and development of complex biologics capable of addressing some of the toughest challenges in oncology drug development.

Shares of PPBT are up 81.8% at $1.06 in Wednesday trading.

Sponsored: